Optimizing the Post-Car T Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel.
BLOOD ADVANCES（2024）
Key words
Access,lymphoma CAR T,axi-cel,tisa-cel,liso-cel,REMS monitoring,non-relapse mortality,CRS,ICANS,infections,access
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined